Prevalence of Birt-Hogg-Dubé syndrome in patients with apparently primary spontaneous pneumothorax.

References 1 Rossi A, van der Molen T, del Olmo R, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J 2014; 44: 1548–1556. 2 Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2010. Available from: http://www.goldcopd.org/uploads/users/files/GOLDReport_ April112011.pdf Date last updated: April 11, 2011. Date last accessed: Oct 14. 3 Calverley PMA. What to use INSTEAD of inhaled corticosteroids in COPD? Eur Respir J 2014; 44: 1391–1393. 4 Rossi A, Guerriero M, Corrado A, et al. Withdrawal of inhaled corticosteroid can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res 2014; 15: 77. 5 Agustì A, Fabri LM. Inhaled steroids in COPD: when should they be used? Lancet Respir Med 2014; 2: 869–871. 6 Lapperre TS, Snoeck-Stroband JB, Gosman MME, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Int Med 2009; 151: 517–527. 7 Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789. 8 Suissa S. Number needed to treat in COPD: exacerbations versus pneumonias. Thorax 2013; 68: 540–543. 9 Wouters EFM, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/ fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005; 60: 480–487. 10 Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014; 371: 1285–1294. 11 Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128–1138. 12 Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Med 2003; 167: 418–424. 13 Contoli M, Baraldo S, Marku B, et al. Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up. J Allergy Clin Immunol 2010; 125: 830–837. 14 Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med 2012; 106: 989–997.